EGFR and neoplasm: Targeting MUC1-C with an antibody-drug conjugate (M1C ADC) is effective against NSCLC HCC827 cells with an activating EGFR(del E746-A750) mutation sensitive to TKIs growing in vitro and as tumor xenografts.60 However, it is not known if the M1C ADC is active in settings of NSCLC TKI resistance.